| CEO Name | Andrew Obenshain |
| Nationality | United States |
| Net Worth Estimation | $5 million |
Andrew Obenshain's net worth, estimated at around $5 million, stems primarily from his salary, stock options, and equity grants as CEO of Bluebird Bio, along with his prior executive roles in the biotech industry. Public filings with the SEC reveal his compensation package, including stock awards, which heavily influence his net worth estimate.
Andrew Obenshain, CEO of Bluebird Bio, has an estimated net worth of $5,000,000, which is 5% of the maximum ($80,000,000) and 50% of the minimum ($10,000,000) for biotechnology CEOs. His net worth is significantly below the typical range for leaders in this business category.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Andrew Obenshain Performance in Bluebird Bio
Andrew Obenshain, CEO of Bluebird Bio, demonstrates visionary leadership by steering the company towards innovative gene therapy advancements. His decisive actions in strategic partnerships and pipeline prioritization have optimized operational performance and accelerated clinical development. Under his leadership, Bluebird Bio has strengthened its market position and expanded its impact in rare disease treatment.
Latest News
Bluebird Bio Agrees to Take-Private Deal as Gene Therapy Pioneer Faces Cash Crunch
Struggling to commercialize its FDA-approved gene therapies, Bluebird Bio will be acquired by Carlyle Group and SK Capital Partners for $3 per share, with potential future payouts if sales targets are met, while new CEO David Meek (ex-Mirati, Ipsen) is set to lead the now-private company. The transaction aims to secure the capital needed to scale delivery of Bluebird's life-changing therapies for blood disorders and rare brain diseases, following years of financial strain and strategic review.
Source: http://www.biopharmadive.com/news/bluebird-buyout-private-carlyle-sk-capital/740602/